Novo Nordisk’s Experimental GLP-1 Drug Shows Weight Loss, Blood Sugar Levels Reduction In Study
Synopsis
The trial was investigating the efficacy, safety, and pharmacokinetics of once-weekly subcutaneous amycretin and once-daily oral amycretin compared to placebo in 448 people with type 2 diabetes.
Novo Nordisk on Tuesday said that a mid-stage trial evaluating Amycretin in people with type 2 diabetes yielded positive outcomes in both weight loss and reduction in average blood sugar levels.
Amycretin showed statistically significant weight loss of up to 14.5% at 36 weeks and demonstrated statistically significant reductions in average blood sugar levels as measured by HbA1c blood test, the company said.
The trial investigated the efficacy, safety, and pharmacokinetics of once-weekly subcutaneous amycretin and once-daily oral amycretin compared with placebo in 448 people with type 2 diabetes inadequately controlled on metformin. About 40% of the study participants also used a class of drugs known as SGLT2 inhibitors to manage their diabetes before joining the study.
Amycretin belongs to the class of drugs known as GLP-1s, used to treat diabetes and obesity, similar to Novo’s blockbuster drugs Wegovy and Ozempic.
Get updates to this developing story directly on Stocktwits.<
Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business.